@article{ref1,
title="Clinical effects of buspirone on intractable self-injury in adults with mental retardation",
journal="Journal of the American Academy of Child and Adolescent Psychiatry",
year="1994",
author="Ricketts, R. W. and Goza, A. B. and Ellis, C. R. and Singh, Y. N. and Chambers, S. and Singh, N. N. and Cooke, J. C.",
volume="33",
number="2",
pages="270-276",
abstract="OBJECTIVE: The efficacy of buspirone in controlling self-injurious behavior was examined in five individuals with mental retardation. Buspirone was used alone in two individuals and as an adjunct to thioridazine in the other three. METHOD: Standard behavioral observation methods were used to collect data on the number of self-injurious responses of the individuals during baseline and several doses of buspirone in an open trial. RESULTS: When compared with baseline levels, all five individuals showed some response to buspirone, with reductions in self-injury ranging from 13% to 72%, depending on the dose. The most effective dose of buspirone was 30 mg/day for three individuals and 52.5 mg/day for the other two. These individuals were maintained for 6 to 33 weeks on their most effective dose. Coexistent symptoms of anxiety did not predict a favorable response to buspirone therapy. CONCLUSIONS: Buspirone showed a mixed but generally favorable response in controlling intractable self-injury in this and four previous studies reporting similar cases. However, the drug should not be endorsed as a proved treatment for self-injury until similar results have been obtained from well-controlled studies of its efficacy.<p /><p>Language: en</p>",
language="en",
issn="0890-8567",
doi="10.1097/00004583-199402000-00017",
url="http://dx.doi.org/10.1097/00004583-199402000-00017"
}